Dexcom (DXCM) Gross Profit (2010 - 2026)

Dexcom (DXCM) has reported Gross Profit for 17 consecutive years, with $830.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Profit rose 20.5% year-over-year to $830.0 million in Q2 2026; TTM through Jun 2026 was $3.1 billion, a 22.83% increase from a year earlier, with the FY2025 full-year figure at $2.8 billion, up 14.92% from the prior year.
• Gross Profit was $830.0 million for Q2 2026 at Dexcom, up from $750.3 million in the prior quarter.
• Over five years, Gross Profit peaked at $830.0 million in Q2 2026 and troughed at $398.1 million in Q1 2022.
• A 5-year average of $610.7 million and a median of $608.6 million in 2023 frame the typical range for Gross Profit.
• Across the five-year window, Gross Profit decreased 4.73% in 2024 and climbed 27.39% in 2026, its largest moves.
• Over 5 years, Gross Profit stood at $541.3 million in 2022, then climbed by 21.3% to $656.6 million in 2023, then decreased by 0.12% to $655.8 million in 2024, then rose by 20.88% to $792.7 million in 2025, then climbed by 4.71% to $830.0 million in 2026.
• The last three Gross Profit figures came in at $830.0 million (Q2 2026), $750.3 million (Q1 2026), and $792.7 million (Q4 2025), per Business Quant data.